Neurocritical Care News

Subcallosal cingulate gyrus deep brain stimulation was generally safe and significantly improved depressive symptoms in patients with treatment-resistant depression, with results sustained up to 7 years, according to research.

A Boston-area clinical stage drug discovery and development company announced $6 million in pre-Series B bridge financing to advance a novel cerebroprotectant therapeutic intended to treat a broad range of acute brain injuries.

Lumbar drainage following an aneurysmal subarachnoid hemorrhage was effective at reducing infarction and decreased rates of unfavorable neurological outcome at 6 months, according to data published in JAMA Neurology.

A California-based nonprofit and a biotechnology firm announced the activation of novel biologic ADI-PEG 20 in the GBM AGILE platform trial, a study that evaluates therapies for individuals with newly diagnosed or recurring glioblastoma.

The FDA has approved once-daily Ingrezza capsules for adults with chorea associated with Huntington’s disease.

An Italian pharmaceutical company and a Boston-area biotechnology research firm announced a partnership to advance a novel blood-brain barrier-crossing platform technology for those with lysosomal storage disorders.

Traumatic brain injury in older adults was linked to alterations in self-perception, social life, ability to perform daily tasks and deterioration in quality of life for up to 5 years, according to research presented in Brain and Spine.

A Canadian firm has announced completion of a round of financing that netted almost $3.4 million for further commercialization of its cognitive performance software in clinics across the United States.

The FDA has granted 510(k) clearance to a Canadian neuroimaging company for its quantitative imaging software, which assists neurologists and radiologists dealing with brain white matter issues for adjunctive care.

A Virginia-based biotech company has announced dosing of the first patient in a phase 2 clinical trial examining safety and efficacy of its investigational anti-inflammatory peptide, RLS-0071, to treat hypoxic ischemic encephalopathy in newborns.